Dear

XIAFLEX® (COLLAGENASE CLOSTRIDIUM HISTOLYTICUM)
PRODUCT DISCONTINUATION FROM 28 JUNE 2019

We are writing to inform you that distribution of XIAFLEX® (collagenase clostridium histolyticum) will be discontinued in New Zealand from 28 June 2019. This is the result of a business decision made by Actelion Pharmaceuticals Pty Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, and not the result of safety or efficacy considerations of XIAFLEX®.

XIAFLEX® has been made available in Australia and New Zealand pursuant to an agreement between Actelion and Endo Ventures Limited and has been distributed in New Zealand by Health Care Logistics on behalf of Actelion. It has provided a non-surgical option for patients with Dupuytren's Contracture and Peyronie's Disease.

Supply of XIAFLEX® for New Zealand will cease after 28 June 2019. You can continue to order XIAFLEX® through the usual channels between now and 28 June 2019. Certified doctors can continue to prescribe, and pharmacists can continue to dispense, XIAFLEX® purchased prior to 28 June. There will however, be no further certification of new doctors on using and administering XIAFLEX® in New Zealand.

The approval of XIAFLEX® will lapse once all product has been depleted from the market which we expect to be sometime in 2020. We will notify you at least three months before this occurs.

Our primary concern is to ensure that patients currently treated with XIAFLEX® are appropriately managed. Unexpired stock circulating in the market after 28 June can continue to be used by those healthcare professionals who are trained and authorised to administer XIAFLEX® under the existing controlled distribution process.

Please refer to the XIAFLEX® Datasheet, available from Actelion Medical Information or https://www1.actelion.com.au/products/index or from the Medsafe website should you need any information on this product.

Actelion is committed to monitoring the safety of our products. We encourage healthcare professionals to report any suspected adverse events for our products to the Centre for Adverse Reactions Monitoring. The easiest way to do this is via the online reporting form, available at: https://nzphvc.otago.ac.nz/report/. Alternatively, you can phone 03 479 7247 or email carmnz@otago.ac.nz.

If you have further questions in regards to the withdrawal of XIAFLEX®, please contact Actelion Medical Information on +612 9486 4600 or medinfo_au@its.jnj.com.

Yours sincerely,



Kate Norton
Actelion Business Unit Head

Dr Sophie Glover-Koudounas
Executive Director, Medical & Scientific Affairs - Janssen